
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune is a well-capitalized biopharmaceutical company working towards developing therapies for serious liver diseases and metabolic disorders. With key candidate pemvidutide in late-stage development for multiple indications, including AUD and ALD, and the company's strong financial position, there is a high potential for pemvidutide to become a successful and commercially viable treatment option. Additionally, upcoming catalysts such as data presentations at EASL 2026 and a potentially earlier completion of enrollment in the ALD trial add further upside potential for the stock.
Bears say
Altimmune is expected to face challenges with the success and commercialization of its key candidate, pemvidutide, due to its limited PoS in AUD and ALD and potential risks associated with clinical development, competition, pricing, reimbursement, and business development. The company also faces potential dilution for existing shareholders with an expected equity capital raise in 2029E. Overall, this assessment leads to a negative outlook for Altimmune's stock due to the uncertainties and risks involved in the company's pipeline and financials.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares